CR10494A - Composiciones farmaceuticas estabilizadas que comprenden fesoterodina - Google Patents

Composiciones farmaceuticas estabilizadas que comprenden fesoterodina

Info

Publication number
CR10494A
CR10494A CR10494A CR10494A CR10494A CR 10494 A CR10494 A CR 10494A CR 10494 A CR10494 A CR 10494A CR 10494 A CR10494 A CR 10494A CR 10494 A CR10494 A CR 10494A
Authority
CR
Costa Rica
Prior art keywords
pharmaceutical compositions
fesoterodine
stabilized pharmaceutical
include fesoterodine
stabilized
Prior art date
Application number
CR10494A
Other languages
English (en)
Spanish (es)
Inventor
Christoph Arth
Hans-Jurgen Mika
Michael Komenda
Hans Lindner
Fatima Bicane
Kerstin Paulus
Meike Irngartinger
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38521333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10494(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of CR10494A publication Critical patent/CR10494A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CR10494A 2006-06-09 2008-12-11 Composiciones farmaceuticas estabilizadas que comprenden fesoterodina CR10494A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06011941 2006-06-09
EP06011942 2006-06-09
EP06011943 2006-06-09

Publications (1)

Publication Number Publication Date
CR10494A true CR10494A (es) 2009-01-19

Family

ID=38521333

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10494A CR10494A (es) 2006-06-09 2008-12-11 Composiciones farmaceuticas estabilizadas que comprenden fesoterodina

Country Status (37)

Country Link
EP (1) EP2029134B1 (enExample)
JP (2) JP4743321B2 (enExample)
KR (1) KR101316773B1 (enExample)
CN (1) CN101466371B (enExample)
AP (1) AP2416A (enExample)
AR (1) AR061289A1 (enExample)
AT (1) ATE517619T1 (enExample)
AU (1) AU2007255408B2 (enExample)
BR (1) BRPI0712865B1 (enExample)
CA (1) CA2652712C (enExample)
CR (1) CR10494A (enExample)
CU (1) CU23850B1 (enExample)
CY (1) CY1111934T1 (enExample)
DK (1) DK2029134T3 (enExample)
EA (1) EA015909B9 (enExample)
EC (1) ECSP089010A (enExample)
ES (1) ES2370943T3 (enExample)
GT (1) GT200800276A (enExample)
HR (1) HRP20110776T1 (enExample)
IL (2) IL195732A (enExample)
MA (1) MA30504B1 (enExample)
MX (1) MX2008015736A (enExample)
MY (1) MY146574A (enExample)
NI (1) NI200800318A (enExample)
NL (1) NL2000690C2 (enExample)
NO (1) NO341980B1 (enExample)
NZ (1) NZ572616A (enExample)
PE (2) PE20080331A1 (enExample)
PL (1) PL2029134T3 (enExample)
PT (1) PT2029134E (enExample)
RS (1) RS51973B (enExample)
SI (1) SI2029134T1 (enExample)
TN (1) TNSN08505A1 (enExample)
TW (2) TWI397409B (enExample)
UY (1) UY30394A1 (enExample)
WO (1) WO2007141298A1 (enExample)
ZA (1) ZA200806411B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009122303A2 (en) * 2008-04-04 2009-10-08 Actavis Group Ptc Ehf Novel mandelate salt of fesoterodine
IT1392082B1 (it) 2008-12-10 2012-02-09 Chemi Spa Nuove forme solide della fesoterodina fumarato
WO2010130392A1 (de) 2009-05-11 2010-11-18 Ratiopharm Gmbh Desfesoterodin in form eines weinsäuresalzes
EP2316432A1 (de) 2009-10-30 2011-05-04 ratiopharm GmbH Zusammensetzung enthaltend Fesoterodin und Ballaststoffe
US20130172411A1 (en) * 2010-03-22 2013-07-04 Cadila Healthcare Limited Stable pharmaceutical compositions comprising fesoterodine
TWI520732B (zh) * 2011-01-18 2016-02-11 輝瑞有限公司 固體分子分散液
EP2508173A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Stabilized pharmaceutical composition comprising fesoterodine
EP2508175A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof
WO2013054337A1 (en) * 2011-07-04 2013-04-18 Cadila Healthcare Limited Extended release pharmaceutical compositions of fesoterodine
WO2013046194A2 (en) * 2012-05-18 2013-04-04 Alembic Pharmaceuticals Limited The novel reference markers for fesoterodine fumarate
US20150182629A1 (en) * 2012-07-02 2015-07-02 Hetero Research Foundation Stable compositions of fesoterodine
JP6356684B2 (ja) 2012-11-02 2018-07-11 マレイ・アンド・プール・エンタープライゼズ・リミテッド コルヒチン誘導体の投与による心血管イベントの処置または予防
EA037375B1 (ru) 2013-04-16 2021-03-22 Марри Энд Пул Энтерпрайзес Лимитед Составы с замедленным высвобождением, содержащие колхицин, и способы их применения
ES2870718T3 (es) * 2013-04-16 2021-10-27 Murray & Poole Entpr Ltd Formulación de liberación mantenida de la colchicina y métodos para establecer los mismos
CZ2014400A3 (cs) 2014-06-09 2015-12-16 Zentiva, K.S. Stabilizovaná formulace fesoterodinu
CN105687154A (zh) * 2014-11-27 2016-06-22 合肥信风科技开发有限公司 含非索罗定的药用组合物及其制备方法
WO2019011393A1 (en) 2017-07-12 2019-01-17 Rontis Hellas S.A. EXTENDED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING FESOTERODINE AND PREPARATION METHOD THEREOF
WO2019132832A1 (en) * 2017-12-25 2019-07-04 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tablet compositions of fesoterodine fumarate
TR201721437A2 (tr) * 2017-12-25 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fesoterodi̇ni̇n modi̇fi̇ye salim sağlayan formülasyonlari
KR102018495B1 (ko) * 2018-03-13 2019-09-05 충북대학교 산학협력단 과민성 방광의 치료를 위한 서방형의 이중층 정제 및 이의 제조방법
CA3094551C (en) 2018-04-26 2024-01-02 Rontis Hellas S.A. Extended release pharmaceutical composition containing fesoterodine and process for the preparation thereof
CN110151720B (zh) * 2019-05-09 2019-12-17 合肥信风科技开发有限公司 含非索罗定的药用组合物及其制备方法
KR20230028535A (ko) * 2020-06-30 2023-02-28 임브리아 파마슈티칼스, 인크. 트리메타지딘의 변형 형태의 변형 방출 제제
JPWO2023145486A1 (enExample) * 2022-01-28 2023-08-03

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002505282A (ja) 1998-03-03 2002-02-19 塩野義製薬株式会社 ホスホリパーゼ阻害剤の［［３−（２−アミノ−１，２−ジオキソエチル）−２−エチル−１−フェニルメチル）−１ｈ−インドール−４−イル］オキシ］酢酸ナトリウムを含む薬学的組成物
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE19955190A1 (de) 1999-11-16 2001-06-21 Sanol Arznei Schwarz Gmbh Stabile Salze neuartiger Derivate von 3,3-Diphenylpropylaminen
DE10224107A1 (de) * 2002-05-29 2003-12-11 Gruenenthal Gmbh Kombination ausgewählter Opioide mit anderen Wirkstoffen zur Therapie der Harninkontinenz
DE10315878B4 (de) 2003-04-08 2009-06-04 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung

Also Published As

Publication number Publication date
IL195732A (en) 2013-09-30
ATE517619T1 (de) 2011-08-15
MA30504B1 (fr) 2009-06-01
NL2000690C2 (nl) 2008-04-01
AU2007255408A1 (en) 2007-12-13
UY30394A1 (es) 2007-11-30
CU20080235A7 (es) 2011-04-26
DK2029134T3 (da) 2011-10-17
EA015909B1 (ru) 2011-12-30
WO2007141298A1 (en) 2007-12-13
CY1111934T1 (el) 2015-11-04
JP4743321B2 (ja) 2011-08-10
RS51973B (sr) 2012-02-29
TNSN08505A1 (fr) 2010-04-14
CA2652712C (en) 2014-04-01
AR061289A1 (es) 2008-08-20
NZ572616A (en) 2010-11-26
EA015909B9 (ru) 2012-03-30
AP2416A (en) 2012-06-01
ECSP089010A (es) 2009-01-30
EA200802444A1 (ru) 2009-06-30
KR20090026135A (ko) 2009-03-11
PL2029134T3 (pl) 2011-12-30
NO341980B1 (no) 2018-03-05
TW201336491A (zh) 2013-09-16
JP2011140498A (ja) 2011-07-21
HK1128626A1 (en) 2009-11-06
CN101466371B (zh) 2011-10-05
TW200814992A (en) 2008-04-01
ES2370943T3 (es) 2011-12-23
EP2029134A1 (en) 2009-03-04
PE20080331A1 (es) 2008-06-19
HRP20110776T1 (hr) 2011-11-30
SI2029134T1 (sl) 2012-01-31
AP2008004673A0 (en) 2008-12-31
NO20090141L (no) 2009-01-09
GT200800276A (es) 2009-06-18
NL2000690A1 (nl) 2007-12-11
ZA200806411B (en) 2009-05-27
EP2029134B1 (en) 2011-07-27
JP4781489B2 (ja) 2011-09-28
IL220800A (en) 2015-03-31
KR101316773B1 (ko) 2013-10-15
TWI520735B (zh) 2016-02-11
JP2009539802A (ja) 2009-11-19
BRPI0712865A2 (pt) 2012-12-18
PT2029134E (pt) 2011-11-02
IL195732A0 (en) 2009-09-01
CA2652712A1 (en) 2007-12-13
PE20120476A1 (es) 2012-04-20
MY146574A (en) 2012-08-30
MX2008015736A (es) 2009-01-09
BRPI0712865B1 (pt) 2021-08-17
CU23850B1 (es) 2012-10-15
AU2007255408B2 (en) 2013-03-14
TWI397409B (zh) 2013-06-01
NI200800318A (es) 2011-01-12
CN101466371A (zh) 2009-06-24

Similar Documents

Publication Publication Date Title
CR10494A (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
DK2068822T4 (da) Selvpræserverede vandige farmaceutiske sammensætninger
CL2008000789A1 (es) Compuestos derivados de adenina; composicion farmaceutica que comprende a dichos compuestos, utiles para tratar enfermedades alergicas, virales o cancer, entre otras.
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
CL2007003797A1 (es) Compuestos derivados de pirrolo piridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la enfermedad de alzheimer, parkinson, cancer, entre otras enfermedades.
NO20084368L (no) Stabile emulsjonsformuleringer
EP1984009A4 (en) PHARMACEUTICAL COMPOSITIONS WITH IMPROVED STABILITY
AR083679A1 (es) Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos
BRPI0814687A2 (pt) MÉTODO IN VITRO PARA INIBIR UM MEMBRO DA FAMÍLIA GTPase DE Rho, COMPOSTO, E, COMPOSIÇÃO FARMACÊUTICA.
DK2068839T3 (da) Farmaceutiske sammensætninger omfattende nilotinib eller salt deraf
CL2007003614A1 (es) Compuestos derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona; composicion farmaceutica que comprende a dicho compuesto; procedimiento de preparacion; y uso del compuesto en el tratamiento de trastornos del metabolismo, como diabetes mellitus, dis
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
GT200900329A (es) Desodorante basado en propilenglicol/glicerina
BRPI0713306A8 (pt) Composição farmacêutica compreendendo amlodipina e losartan
AR067770A1 (es) Derivados de tiazol y ditiazol para el tratamiento de diabetes
CR11418A (es) Trans-clomifeno para el sindrome metabolico
ECSP088689A (es) NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS
CL2007003636A1 (es) Compuestos derivados de benzoimidazol sustituidos con sulfonilfenil; proceso para preparar dichos compuestos; composicion farmaceutica que comprenden dichos compuestos; y su uso para tratar el dolor cronico o agudo, debido a una enfermedad que causa
CR8788A (es) Orodispersible pharmaceutical compositions for oromucosal or sublingual administration of agomelatine
CO6270306A2 (es) Compuesto inhibidor de glicogeno fosforilasa y composicion farmaceutica del mismo
CL2007002315A1 (es) Compuestos derivados de piridina;composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades o trastornos que comprenden el dolor y/o sindrome del intestino irritable.
BRPI0713343A2 (pt) Composições farmacêuticas contendo anticorpo monoclonal anti-idiolípico anti-ca-125 e alumínio
DOP2008000067A (es) Composiciones farmaceuticas estabilizada que comprenden fesoterodina.
AR068608A1 (es) Neramexano para el tratamiento de nistagmo